Company Valuation: Imexpharm Corporation

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027
Market Cap 1 5,187,048 4,013,628 3,962,167 7,238,421 8,085,471 6,345,169 -
Change - -22.62% -1.28% 82.69% 11.7% -21.52% -
Enterprise Value (EV) 5,187,048 4,013,628 3,962,167 7,238,421 8,085,471 6,345,169 6,345,169
Change - -22.62% -1.28% 82.69% 11.7% -21.52% 0%
P/E 29.9x 17.2x 15.6x 24.3x 26.6x 18x 16.6x
PBR 2.89x 2.11x 1.9x 3.32x - 2.55x 2.33x
PEG - 0.5x 1.68x 1.4x 11.68x 1.1x 1.96x
Capitalization / Revenue 4.1x 2.44x 1.99x 3.28x 3.31x 2.39x 2.2x
EV / Revenue 0x 0x 0x 0x 0x 2.39x 2.2x
EV / EBITDA - - - - - - -
EV / EBIT 0x 0x 0x 0x 0x 12.9x 11.9x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Dividend per Share 2 649.4 - - 500 - 1,000 1,000
Rate of return 1.93% - - 1.06% - 2.41% 2.41%
EPS 2 1,126 1,513 1,653 1,932 1,976 2,304 2,499
Distribution rate 57.7% - - 25.9% - 43.4% 40%
Net sales 1 1,266,597 1,643,707 1,994,037 2,205,120 2,441,085 2,659,000 2,881,000
EBITDA 299,271 - 457,049 521,703 - - -
EBIT 1 234,475 300,992 374,407 403,285 445,003 490,000 532,000
Net income 1 189,095 233,964 299,556 320,862 349,138 394,000 428,000
Net Debt - - - - - - -
Reference price 2 33,679.65 26,060.61 25,727.27 47,000.00 52,500.00 41,500.00 41,500.00
Nbr of stocks (in thousands) 154,011 154,011 154,007 154,009 154,009 154,009 -
Announcement Date 20/01/22 17/01/23 19/01/24 20/01/25 20/01/26 - -
1VND in Million2VND
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
18.01x - - - 243M
35.49x12.92x26.31x0.56% 1,085B
27.65x6.35x17.24x2.06% 624B
30.17x7.39x15.12x2.74% 442B
17.88x4.44x10.99x2.98% 332B
22.38x4.7x13.12x1.86% 277B
21.53x5.52x13.36x2.86% 282B
14.08x5.27x10.83x3.55% 217B
23.79x6.31x11.13x2.77% 196B
-47.8x5.8x32.25x2.41% 167B
Average 16.32x 6.52x 16.71x 2.42% 362.22B
Weighted average by Cap. 24.02x 7.99x 18.49x 1.97%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. IMP Stock
  4. Valuation Imexpharm Corporation